The new generation of anti-epileptic drugs

Bibliography

• SANDER JWAS, HART YM, JOHNSON AL, SHORVON SD: National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet (1990) 336:1267–1271.
   PubMed Web of Science ®Google Scholar
• SANDER JWAS, SHORVON SD: Incidence and prevalence studies in epilepsy and their methodological problems: a review. J. Neurol. Neurosurg. Psychiat. (1987) 50:829–839.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the methodology of epidemiology as used in the study of epilepsy.
   Google Scholar
• COCKERELL OC, HART YM, SANDER JWAS, SHORVON SD: The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. (1994) 18:249–260.
   PubMed Web of Science ®Google Scholar
• JACOBY A, BUCK D, BAKER G, MCNAMEE P, GRAHAM-JONES S, CHADWICK D: Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia (1998) 39:776–786.
   PubMed Web of Science ®Google Scholar
• SANDER JWAS: Some aspects of prognosis in the epilepsies: a review. Epilepsia (1993)34:1007–1016.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN: Phenobarbitone to gabapentin: a guide to 82 years of antiepileptic drug pharmacokinetic interactions. Seizure (1994) 3:163–170.
   PubMedGoogle Scholar
• PATSALOS PN, DUNCAN JS: Antiepileptic drugs: a review of clinically significant drug interactions. Drug Safety (1993) 9:158–184.
   Google Scholar
• MURRAY MI, HALPERN MT, LEPPIK IE: Cost of refractory epilepsy in adults in the USA. Epilepsy Res. (1996) 23:139–148.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JWAS: Overtreatment with antiepileptic drugs: how extensive is the problem CNS Drugs (1994) 2:355–340.
   Web of Science ®Google Scholar
• PATSALOS PN: New anti-epileptic drugs. Ann. Clin. Biochem. (1999) 36:10–19.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of vigabatrin, lamotrigine, gabapentin and topiramate withparticular emphasis on the usefulness of therapeutic drug monitoring in optimising therapy with these drugs.
   Google Scholar
• PATSALOS PN, DUNCAN JS: New antiepileptic drugs. A review of their current status and clinical potential. CNS Drugs (1994) 2:40–77.
   Web of Science ®Google Scholar
• PATSALOS PN, SANDER JWAS: Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Safety (1994) 11:37–67.
   PubMed Web of Science ®Google Scholar
• BRODIE MJ, RICHENS A, YUEN AWC: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet (1995) 345:476–479.
   PubMed Web of Science ®Google Scholar
• WALKER MC, SANDER JWAS: The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology (1996) 46:912–914.
   PubMed Web of Science ®Google Scholar
• ••This paper discusses the outcome measures that should be used in anti-epileptic drug trials.
   Google Scholar
• MARSON AG, KADIR ZA, CHADWICK DW: New anti-epileptic drugs: a systematic review of their efficacy and tolerability. Br. Med. J. (1996) 313:1169–1174.
   PubMed Web of Science ®Google Scholar
• ••This is an interesting meta-analysis of the tolerability and efficacy of the new anti-epilepticdrugs in all of the randomised placebo-controlled clinical trials. No difference was observed between the different drugs.
   Google Scholar
• MARSON AG, KADIR ZA, HUTTON JL, CHADWICK DW: The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia (1997) 38:859–880.
   PubMed Web of Science ®Google Scholar
• WALKER MC, LI LM, SANDER JWAS: Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. Br. Med. J. (1996) 313:1184–1185.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D, RUNDFELDT C: Anti-epileptic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. (1998) 285:474–479.
   Google Scholar
• EKE T, TALBOT JF, LAWDEN MC: Severe persistent visual field constriction associated with vigabatrin. Br. Med. J. (1997) 314:180–181.
   PubMed Web of Science ®Google Scholar
• •The first report of vigabatrin associated visual field defects.
   Google Scholar
• KNOWLES S, SHAPIRO L, SHEAR NH: Serious dermatological reactions in children. Curr.Opin. Pediatr. (1997) 9:388–395.
   PubMed Web of Science ®Google Scholar
• •An interesting review of the lamotrigine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.
   Google Scholar
• O'NEIL MG, PERDUN CS, WILSON MB, MCGOWN ST, PATEL S: Felbamate-associated fatal acute hepatic necrosis. Neurology (1996) 46:1457–1459.
   PubMed Web of Science ®Google Scholar
• RIVA R, ALBANI F, CONTIN M, BARUZZI A: Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin. Pharmacokin. (1996) 31:470–493.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, SCHMIDT D: Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation Epilepsy Res. (1994) 17:95–134.
   Google Scholar
• SVEINBJORNSDOTTIR S, SANDER JWAS, UPTON D, et al.: The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res. (1993) 16:165-174. Whilst D-CPP-ene was well-tolerated in human volunteers, it had unacceptable side-effects
   PubMedGoogle Scholar
• • in patients with epilepsy. This study emphasis that the 'epileptic' brain is not the same as the 'non-epileptic' brain.
   Google Scholar
• SEMBA J, CURZON G, PATSALOS PN: Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br. J. Pharmacol. (1993) 108:1117–1124.
   PubMed Web of Science ®Google Scholar
• NASHEF L, BROWN S: Epilepsy and sudden death. Lancet (1996) 348:1324–1325.
   PubMed Web of Science ®Google Scholar
• BINNIE C: Design of clinical anti-epileptic drug trials. Seizure (1995) 4:187–192.
   PubMedGoogle Scholar
• ••A thorough review of clinical trial designs used in evaluating new anti-epileptic drugs.
   Google Scholar
• STALEY KJ, SOLDO BL, PROCTOR WR: Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science (1995) 269:977–981.
   PubMed Web of Science ®Google Scholar
• FISHER RS, CYSYK BJ, LESSER RP, et al.: Dextromethorphan for treatment of complex partial seizures. Neurology (1990) 40:547–549.
   PubMed Web of Science ®Google Scholar
• DURING MJ, SPENCER DD: Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. (1992) 32:618–624.
   PubMed Web of Science ®Google Scholar
• LEPPIK IE: Felbamate. Epilepsia (1995) 36 (Suppl. 2):566–572.
   PubMedGoogle Scholar
• PETROFF OAC, ROTHMAN DL, BEHAR KL, LAMOUREAUX D, MATTSON RH: The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann. Neurol. (1996) 39:95–99.
   PubMed Web of Science ®Google Scholar
• •Gabapentin raises GABA brain concentrations. This effect was not seen in animals and raises questions as to the exact mechanism of action of gabapentin.
   Google Scholar
• GEE NS, BROWN JP, DISSANAYAKE VUK, OFFORD J, THURLOW R, WOODRUFF GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the a2ö subunit of a calcium channel. J. Biol. Chem. (1996) 271:5768–5776.
   PubMed Web of Science ®Google Scholar
• WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmac. Ther. (1995) 67:351–384.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of new anti-epileptic drug pharmacokinetics, with particular emphasison clinically important pharmacokinetic characteristics.
   Google Scholar
• SUZDAK P, AAS JANSEN J: A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia (1995) 36:612–626.
   PubMed Web of Science ®Google Scholar
• SHANK RP, GARDOCHI JF, VAUGHT JL, et al.: Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia (1994) 35:450–460.
   PubMed Web of Science ®Google Scholar
• SHARIEF MK, SINGH P, SANDER JWAS, PATSALOS PN, SHORVON SD: Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J. Epilepsy (1996) 9:106–112.
   Google Scholar
• •This was the first report on the significant efficacy of levetiracetam (ucb L059) in patients with intractable epilepsy.
   Google Scholar
• STEIN U, KLESSING K, CHATTERJEE SS: Losigamone. Epilepsy Res. (1991) 3(Suppl.) :129–133.
   Google Scholar
• HU RQ, DAVIES JS: The effect of the desglycine metabolite of remacemide on cortical wedges prepared from DBA/2 mice. Eur. J. Pharmacol. (1995) 287:251–256.
   PubMed Web of Science ®Google Scholar
• KAPEGHIAN JC, MADAN A, PARKINSON A, TRIPP SL, PROBST A: Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential interactions in vitro. Epilepsia (1996) 37 (Suppl. 5):26.
   Google Scholar
• MAURIZIS JC, MADELMONT JC, RAPP M, et al.: Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazoly1) (D2916) in male and female rats. Drug Metab. Dispos. (1997) 25:33–39.
   PubMed Web of Science ®Google Scholar
• HADAD S, BIALER M: Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res. (1995) 12:905–910.
   PubMed Web of Science ®Google Scholar
• KAPETANOVIC IM, YONEKAWA WD, KUPFERBURG HJ: The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res. (1995) 22:167–173.
   PubMed Web of Science ®Google Scholar
• CARTER RB, WOOD PL, WIELAND S, et al.: Characterization of the anticonvulsant proper-ties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J. Pharmacol. Exp. Ther. (1997) 280:1284–1295.
   PubMed Web of Science ®Google Scholar
• TOBER C, STARK B, ROSTOCK A, BARTSCH R: Anticonvulsant effects of AWD 140–190 on the development of the amygdala kindling in rats. Naunyn Schmiedeberg's Arch. Pharmacol. (1996) 354\(Suppl. 1):R42.
   Google Scholar